@article {Wijnant1901217，作者= {Wijnant，萨拉雷娜塔Alex和德鲁斯，Emmely和Kavousi，玛丽亚姆和史翠，布鲁诺雨果和Terzikhan，Natalie和Lahousse，谎言和Brusselle，盖G.}，标题= {弹道和死亡率保留比受损肺活量测定：Rotterdam研究}，体积= {55}，数= {1}，elocation-ID = {1901217}，年= {2020}，DOI = {10.1183 / 13993003.01217-2019}，出版商= {欧洲呼吸协会}，抽象= {保藏比受损肺活量（棱镜）是一种异质性的条件，但其当然和疾病进展仍有待阐明。我们的目的是检验在一般population.In鹿特丹研究其患病率，轨迹和预后（基于人口的前瞻性队列）我们研究盛行，轨迹以及与肺活量正常（对照组受试者的预后;用力呼气量在1秒（FEV1）/forced vital capacity (FVC) >=0.7, FEV1  >=80\%), PRISm (FEV1/FVC >=0.7, FEV1 \<80\%) and chronic obstructive pulmonary disease (COPD) (FEV1/FVC \<0.7) at two study visits. Hazard ratios with 95\% confidence intervals for mortality (until December 30, 2018) were adjusted for age, sex, body mass index, current smoking and pack-years.Of 5487 subjects (age 69.1{\textpm}8.9 years; 7.1\% PRISm), 1603 were re-examined after 4.5 years. Of the re-examined PRISm subjects, 15.7\% transitioned to normal spirometry and 49.4\% to COPD. Median lung function decline was highest in subjects with incident PRISm (FEV1 -92.8 mL{\textperiodcentered}year-1, interquartile range (IQR) -131.9{\textendash} -65.8 mL{\textperiodcentered}year-1; FVC -93.3 mL{\textperiodcentered}year-1, IQR -159.8{\textendash} -49.1 mL{\textperiodcentered}year-1), but similar in persistent PRISm (FEV1 -30.2 mL{\textperiodcentered}year-1, IQR -67.9{\textendash} -7.5 mL{\textperiodcentered}year-1; FVC -20.1 mL{\textperiodcentered}year-1, IQR -47.7{\textendash}21.7 mL{\textperiodcentered}year-1) and persistent controls (FEV1 -39.6 mL{\textperiodcentered}year-1, IQR -64.3{\textendash}-12.7 mL{\textperiodcentered}year-1; FVC -20.0 mL{\textperiodcentered}year-1, IQR -55.4{\textendash}18.8 mL{\textperiodcentered}year-1). Of 5459 subjects with informed consent for follow-up, 692 (12.7\%) died during 9.3 years (maximum) follow-up: 10.3\% of controls, 18.7\% of PRISm subjects and 20.8\% of COPD subjects. Relative to controls, subjects with PRISm and COPD Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2{\textendash}4 had increased all-cause mortality (PRISm: HR 1.6, 95\% CI 1.2{\textendash}2.0; COPD GOLD 2{\textendash}4: HR 1.7, 95\% CI 1.4{\textendash}2.1) and cardiovascular mortality (PRISm: HR 2.8, 95\% CI 1.5{\textendash}5.1; COPD 2{\textendash}4: HR 2.1, 95\% CI 1.2{\textendash}3.6). Mortality within \<1 year was highest in PRISm, with patients often having cardiovascular comorbidities (heart failure or coronary heart disease; 70.0\%).PRISm is associated with increased mortality and this population encompasses at least three distinct subsets: one that develops COPD during follow-up, a second with high cardiovascular burden and early mortality, and a third with persistent PRISm and normal age-related lung function decline.Preserved ratio impaired spirometry, previously called restrictive spirometry, is a condition associated with increased mortality that encompasses distinct clinical subsets http://bit.ly/2ncclac}, issn = {0903-1936}, URL = {//www.qdcxjkg.com/content/55/1/1901217}, eprint = {//www.qdcxjkg.com/content/55/1/1901217.full.pdf}, journal = {European Respiratory Journal} }